Claims
- 1. A pharmaceutical composition useful for treating bacterial infections in humans and animals which comprises a synergistically effective amount of a pharmaceutically acceptable di-basic salt of MM 17880 which is at least 75% pure and an antibacterially effective amount of amoxycillin, which substance MM 17880 is a di-acidic solid of the molecular formula C.sub.11-14 H.sub.18-25 O.sub.8-11 N.sub.2 S.sub.2 which in the form of a substantially pure di-sodium salt has the following characteristics:
- (a) when present at 0.4% w/w in a freshly prepared KBr disc, it has a characteristic infrared spectrum substantially as shown in FIG. 1;
- (b) it has a characteristic nuclear magnetic resonance spectrum which when taken in deuterium oxide is substantially as shown in FIG. 2;
- (c) it has a characteristic ultra-violet spectrum which in water has an absorption maximum at about 297 n.m. substantially as shown in FIG. 3;
- (d) it possesses antibacterial activity against certain gram-positive and gram-negative organisms, including strains of Bacillus subtilis, Enterobacter cloacae, Escherichia coli, Klebsiella aerogenes, Proteus mirabilis, Salmonella typhimurium, Serratia marcescens and Staphylococcus aureus; and
- (e) when mixed with ampicillin or amoxycillin, it synergizes their antibacterial activity against certain bacteria, including strains of Staphylococcus aureus and Klebsiella aerogenes,
- in combination with a pharmaceutically acceptable carrier.
- 2. A composition according to claim 1 wherein the pharmaceutically acceptable di-basic salt of MM 17880 is at least 80% pure.
- 3. A composition according to claim 1 wherein the pharmaceutically acceptable di-basic salt of MM 17880 is 90% to 100% pure.
- 4. A composition according to claim 1 wherein the pharmaceutically acceptable di-basic salt of MM 17880 is in the form of an alkali metal salt.
- 5. A composition according to claim 1 wherein the pharmaceutically acceptable di-basic salt of MM 17880 is the sodium, potassium, calcium, magnesium, aluminum or ammonium salt.
- 6. A composition according to claim 1 wherein the pharmaceutically acceptable di-basic salt of MM 17880 is in the form of the di-sodium salt.
- 7. A composition according to claim 1 wherein the pharmaceutically acceptable di-basic salt of MM 17880 is in the form of a di-potassium salt.
- 8. A composition according to claim 1 in intramammary administration form.
- 9. A composition according to claim 1 in injectible administration form.
- 10. A composition according to claim 1 in infusible administration form.
- 11. A method of treating bacterial infections in humans and animals which comprises administering to a human or animal in need thereof a synergistically effective amount of a pharmaceutically acceptable di-basic salt of MM 17880 which is at least 75% pure and an antibacterially effective amount of amoxycillin, which substance MM 17880 is a di-acidic solid of the molecular formula C.sub.11-14 H.sub.18-25 O.sub.8-11 N.sub.2 S.sub.2 which in the form of a substantially pure di-sodium salt has the following characteristics:
- (a) when present at 0.4% w/w in a freshly prepared KBr disc, it has a characteristic infrared spectrum substantially as shown in FIG. 1;
- (b) it has a characteristic nuclear magnetic resonance spectrum which when taken in deuterium oxide is substantially as shown in FIG. 2;
- (c) it has a characteristic ultra-violet spectrum which in water has an absorption maximum at about 297 n.m. substantially as shown in FIG. 3;
- (d) it possesses antibacterial activity against certain gram-positive and gram-negative organisms, including strains of Bacillus subtilis, Enterobacter cloacae, Escherichia coll, Klebsiella aerogenes, Proteus mirabilis, Salmonella typhimurium, Serratia marcescens and Staphylococcus aureus; and
- (e) when mixed with ampicillin or amoxycillin, it synergizes their antibacterial activity against certain bacteria, including strains of Staphylococcus aureus and Klebsiella aerogens,
- in combination with a pharmaceutically acceptable carrier.
- 12. A method according to claim 11 wherein the pharmaceutically acceptable di-basic salt of MM 17880 is at least 80% pure.
- 13. A method according to claim 12 wherein the pharmaceutically acceptable di-basic salt of MM 17880 is 90% to 100% pure.
- 14. A method according to claim 11 wherein the pharmaceutically acceptable di-basic salt of MM 17880 is in the form of an alkali metal salt.
- 15. A method according to claim 11 wherein the pharmaceutically acceptable di-basic salt of MM 17880 is the sodium, potassium, calcium, magnesium, aluminum or ammonium salt.
- 16. A method according to claim 11, wherein the pharmaceutically acceptable di-basic salt of MM 17880 is in the form of the di-sodium salt.
- 17. A method according to claim 11 wherein the pharmaceutically acceptable di-basic salt of MM 17880 is in the form of the di-potassium salt.
- 18. A method according to claim 11 wherein the administration is intrammary.
- 19. A method according to claim 11 wherein the administration is by injection.
- 20. A method according to claim 11 wherein the administration is by infusion.
Priority Claims (1)
Number |
Date |
Country |
Kind |
10914/75 |
Mar 1975 |
GBX |
|
CROSS REFERENCE
This is a division of Ser. No. 725,677 filed Sept. 22, 1976, now U.S. Pat. No. 4,162,304, which is a continuation-in-part of Ser. No. 716,953, filed Aug. 23, 1976, now abandoned, and which in turn, is a division of Ser. No. 664,917, filed Mar. 8, 1976, now abandoned.
Divisions (2)
|
Number |
Date |
Country |
Parent |
725677 |
Sep 1976 |
|
Parent |
664917 |
Mar 1976 |
|
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
716953 |
Aug 1976 |
|